Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Invested Capital (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Invested Capital for 7 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 67.27% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 67.27% increase, with the full-year FY2025 number at $1.2 billion, up 67.27% from a year prior.
  • Invested Capital was $1.2 billion for Q4 2025 at Beam Therapeutics, up from $967.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.2 billion in Q4 2025 to a low of $495.5 million in Q1 2021.
  • A 5-year average of $858.1 million and a median of $841.5 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 317.14% in 2021, then fell 25.22% in 2024.
  • Beam Therapeutics' Invested Capital stood at $868.9 million in 2021, then decreased by 13.48% to $751.8 million in 2022, then skyrocketed by 31.97% to $992.1 million in 2023, then decreased by 25.22% to $741.9 million in 2024, then skyrocketed by 67.27% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Invested Capital are $1.2 billion (Q4 2025), $967.2 million (Q3 2025), and $1.1 billion (Q2 2025).